Rab25 Acts as a Promising Novel Bio-Marker in the Prognosis of Patients with Hepatocellular Carcinoma

Zhong Dai
Cancer Hospital of Huanxing, Chaoyang District

Ke-Qing Yao
Cancer Hospital of Huanxing, Chaoyang District

Xing-Sheng Hu ( hfdds@126.com )
Cancer Hospital ,Chinese Academy of Medical Sciences & Peking Union Medical College
https://orcid.org/0000-0001-6268-889X

Yi-Qun Li
Chinese Academy of Medical Sciences & Peking Union Medical College

Yu-Tao Liu
Chinese Academy of Medical Sciences & Peking Union Medical College

Shu-Luan Li
Cancer Hospital of Huanxing, Chaoyang District

Xue Ji
Cancer Hospital of Huanxing, Chaoyang District

Primary research

Keywords: Hepatocellular carcinoma, Rab25, Prognosis

DOI: https://doi.org/10.21203/rs.3.rs-43510/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

**Background:** Rab25 was indicated to be involved in several human tumors. However, the clinical significance of Rab25 in hepatocellular carcinoma (HCC) was still unclear. The purpose of this study was to investigate the expression and prognostic value of Rab25 in HCC.

**Methods:** The relative mRNA expression levels of Rab25 in HCC tissues and adjacent normal tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was used to analyze the relationship between Rab25 expression and clinical characteristics of patients. The prognostic value of Rab25 in HCC was estimated through Kaplan-Meier method and cox regression analysis.

**Results:** Rab25 gene expression level was significantly higher in HCC tissues than that in normal tissues ($P<0.001$). Importantly, the increased Rab25 expression was closely associated with TNM stage ($P=0.024$), metastasis ($P=0.022$) and invasion classification ($P=0.039$). Moreover, patients with high Rab25 expression tended to have obviously shorter overall survival than those with low expression of Rab25 (log rank test, $P<0.001$) via Kaplan-Meier analysis. Univariate and multivariate cox regression analyses revealed that Rab25 was an independent prognostic factor of HCC.

**Conclusions:** Rab25 is up-regulated in HCC and contributes to the progression of this tumor. What's more, Rab25 may be a potential bio-marker for the prognosis of HCC.

Background

Currently, hepatocellular carcinoma (HCC) is a most frequent malignancy worldwide [1]. HCC is one of the major causes of incidence and mortality rates among malignant tumors [2]. The risk factors for the progression of HCC consist of chronic hepatitis virus infection and liver cirrhosis [3]. Although surgical resection is the most common therapies for HCC, the death rate is still high due to the frequent recurrence and high metastasis [4]. In addition, most HCC patients are diagnosed with advanced stages and the current treatments are not effective for them [5]. Because of the above-mentioned reasons, the prognosis of HCC is poor and the 5-year overall survival is very low [6]. Therefore, it is important to find novel biomarkers for the prognosis and targets for the therapy of HCC.

Rab GTPases family plays crucial roles in regulating vesicle transportation [7]. Previous studies had demonstrated that several members of Rab GTPases were involved in some processes, including the progression of human tumors [8, 9]. *Rab25* is a member of the *Rab11* family and located on human chromosome 1q22. *Rab25* gene encodes an intracellular transport protein that participates in the regulation of signal transduction and pathways, including cell proliferation, differentiation and migration of cancers [10]. The expression of *Rab25* was considered to be ubiquitous and enriched in epithelial cells. A growing body of evidence had reported that the aberrant expression of *Rab25* was confirmed in a variety types of tumors [11, 12]. In addition, a study suggested that knockdown of *Rab25* could suppress cell growth, cell cycle progression and induce cell apoptosis of ovarian cancer [13]. Moreover, *Rab25* had
been proven to be up-regulated in HCC, and its over-expression contributed to tumor cell proliferation as well as invasion [14]. However, little is known about the prognostic value of Rab25 in HCC.

In this study, we detected the relative mRNA expression levels of Rab25 in HCC tissues and corresponding adjacent normal tissues. The relationship between Rab25 expression and clinical characteristics of patients was analyzed. The prognostic value of Rab25 was also assessed.

**Methods**

**Patients and samples**

We recruited 132 HCC patients who underwent curative resection at Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College. None of the patients had received any treatments before surgery. Histopathological diagnosis was confirmed by the pathologists with extensive experience. This study was approved by the Ethical Committee of the hospital and the written informed consents were obtained from all patients in advance.

HCC tissues and corresponding adjacent normal tissues were collected from HCC patients and immediately frozen in liquid nitrogen. The tissue samples were stored at –80°C before RNA extraction. The detail clinicopathological characteristics of HCC patients were shown in Table 1. Patients’ follow-up was conducted with 5 years via a telephone or questionnaires. Patients whose deaths were not directly associated with HCC should be excluded from this study.
Table 1
Relationship between *Rab25* expression and clinical features of HCC patients

| Clinical Features          | Cases (n = 132) | *Rab25* expression | \( \chi^2 \) | \( P \) |
|----------------------------|-----------------|---------------------|-------------|---------|
|                            |                 | High (n = 64)       | Low (n = 68) |         |
| Age (years)                |                 |                     |             |         |
| \( \leq 53 \)              | 69              | 31                  | 38          | 0.732   |
| > 53                       | 63              | 33                  | 30          | 0.392   |
| Gender                     |                 |                     |             |         |
| Male                       | 91              | 46                  | 45          | 0.500   |
| Female                     | 41              | 18                  | 23          | 0.480   |
| Liver cirrhosis            |                 |                     |             |         |
| No                         | 42              | 17                  | 25          | 1.582   |
| Yes                        | 90              | 47                  | 43          | 0.208   |
| AFP level (ng/mL)          |                 |                     |             |         |
| \( \leq 20 \)              | 79              | 35                  | 44          | 1.377   |
| > 20                       | 53              | 29                  | 24          | 0.241   |
| Tumor size (cm)            |                 |                     |             |         |
| \( \leq 5 \)              | 74              | 32                  | 42          | 1.853   |
| > 5                         | 58              | 32                  | 26          | 0.173   |
| Differentiation            |                 |                     |             |         |
| Well + Moderate            | 68              | 28                  | 40          | 2.999   |
| Poor                       | 64              | 36                  | 28          | 0.083   |
| TNM stage                  |                 |                     |             |         |
| – –                        | 67              | 26                  | 41          | 5.103   |
| – –                        | 65              | 38                  | 27          | 0.226   |
| Metastasis                 |                 |                     |             |         |
| Negative                   | 89              | 37                  | 52          | 5.226   |
| Positive                   | 43              | 27                  | 16          | 0.039   |
| Invasion classification    |                 |                     |             |         |
| T1 + T2                    | 82              | 34                  | 48          | 4.273   |
Clinical Features | Cases (n = 132) | Rab25 expression | $\chi^2$ | $P$
--- | --- | --- | --- | ---
T3 + T4 | 50 | High (n = 64) | Low (n = 68) | 30 | 20

**RNA extraction and qRT-PCR**

The TRIzol reagent (Invitrogen, USA) was used to isolate total RNA from tissue samples. The reverse transcription was performed with PrimeScript® 1st strand cDNA synthesis kit (Takara, China). SYBR Green PCR kit (Takara, China) was applied to detect the relative mRNA expression of Rab25 in tissues. GAPDH was used as internal control and the relative mRNA quantification of Rab25 expression was calculated by the $2^{-\Delta\Delta^Ct}$ method. Each samples was examined in triplicate.

**Statistical analysis**

SPSS 18.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 5.0 (GraphPad Software Inc., USA) were utilized to perform all the statistical analyses. The data were presented as mean ± standard deviation (SD). The difference between two groups was evaluated via Student’s t-test. And chi-square test was applied to analyze the relationship between Rab25 expression and clinical characteristics of patients. The overall survival of patients with different Rab25 expression was compared by Kaplan-Meier analysis. Univariate and multivariate cox regression analyses were used to estimate the prognostic value of Rab25 in HCC. When $P$ less than 0.05, the difference was considered statistically significant.

**Results**

**Demographic data of the study subjects**

The clinical characteristics of HCC patients were shown in Table 1. 41 female and 91 male patients were enrolled in this study (mean age, 53.37 ± 14.95 years; range, 36–81 years). Among these patients, 90 patients had liver cirrhosis and 79 patients had AFP levels less than 20 ng/mL. 74 tumors were less than 5 cm in size and 58 tumors were more than 5 cm in size. There were 68 cases with well or moderate differentiation and 64 cases with poor differentiation. Of 132 patients, 67 patients were at stage $-$ and 65 patients were at stage $+$. There were 43 patients with positive metastasis and 50 patients of T3 + T4 invasion classification.

**Rab25 expression was up-regulated in HCC patients**

The relative mRNA expression levels of Rab25 in HCC tissues and adjacent normal tissues were detected by qRT-PCR. Compared with normal tissues, Rab25 mRNA expression was significantly increased in HCC tissues ($P < 0.001$, Fig. 1). According to the median Rab25 expression, 132 HCC patients were divided into high Rab25 expression group and low Rab25 expression group.

**Relationship between Rab25 expression and clinical features of HCC patients**
To explore whether *Rab25* was involved in the development of HCC, we analyzed the correlation between its expression and clinical characteristics of patients. As shown in Table 1, a notable correlation was found between *Rab25* expression and TNM stage (*P* = 0.024), metastasis (*P* = 0.022) as well as invasion classification (*P* = 0.039). However, *Rab25* expression was not obviously associated with age, gender, liver cirrhosis, AFP level, tumor size or differentiation (*P* > 0.05, Table 1).

*Increased expression of Rab25 was associated with poor prognosis of HCC patients*

In Kaplan-Meier analysis, the overall survival time of HCC patients with low *Rab25* expression was markedly longer than those with high expression of *Rab25* (log rank test, *P* < 0.001, Fig. 2). To estimate whether *Rab25* expression was associated with the prognosis of HCC, cox regression analysis was conducted. Univariate and multivariate analyses using cox regression analysis revealed that *Rab25* expression (HR = 2.149, 95%CI = 1.276–3.618, *P* = 0.004), TNM stage (HR = 2.041, 95%CI = 1.215–3.429, *P* = 0.007) and metastasis (HR = 1.860, 95%CI = 1.125–3.078, *P* = 0.016) were all correlated with the overall survival and they might be independent prognostic factors of HCC patients (Table 2).
Table 2
Univariate and multivariate cox regression analyses of prognostic factors in patients with HCC patients

| Factors                      | Univariate analysis | Multivariate analysis |
|------------------------------|---------------------|-----------------------|
|                              | HR                  | (95% CI)              | P   | HR                  | (95% CI)              | P   |
| Rab25 (High vs Low)          | 2.512               | 1.503-4.200           | <0.001 | 2.149               | 1.276-3.618           | 0.004 |
| Age (years) (> 53 vs ≤ 53)  | 1.023               | 0.624-1.677           | 0.929 | -                   | -                     | -   |
| Gender (Male vs Female)      | 1.401               | 0.794-2.471           | 0.245 | -                   | -                     | -   |
| Liver cirrhosis (Yes vs No) | 1.353               | 0.776-2.360           | 0.287 | -                   | -                     | -   |
|AFP level (ng/mL) (> 20 vs ≤ 20) | 1.644               | 1.003-2.696           | 0.049 | -                   | -                     | -   |
| Tumor size (cm) (> 5 vs ≤ 5) | 1.659               | 1.010-2.723           | 0.045 | -                   | -                     | -   |
| Differentiation (Poor vs Well + Moderate) | 1.789               | 1.080-2.966           | 0.024 | -                   | -                     | -   |
| TNM stage (I-II vs III)      | 2.211               | 1.322-3.698           | 0.002 | 2.041               | 1.215-3.429           | 0.007 |
| Metastasis (Positive vs Negative) | 2.037               | 1.238-3.353           | 0.005 | 1.860               | 1.125-3.078           | 0.016 |
| Invasion classification (T3 + T4 vs T1 + T2) | 1.749               | 1.066-2.871           | 0.027 | -                   | -                     | -   |

Note: - indicated no data.

Discussion

Rab GTPases family members, belonging to the rat sarcoma (Ras) oncoprotein small GTPases, are key regulators of intracellular vesicle transport that plays an important role in carcinogenesis and tumor progression [7, 15]. It reported that Rab GTPases was associated with several tumor-related processes [8].
Similar to other members of Rab GTPases family, Rab25 had been proven to be specific in epithelial cells and function in various cancers [16]. Previous study had showed that Rab25 could enhance the aggressiveness of tumors through directly interacting with integrin and thereby promoting tumor cell invasion [17]. It also revealed that the aberrant expression of Rab25 might be involved in tumorigenesis, progression and prognosis of neoplasia [18]. However, the clinical significance of Rab25 in HCC is still unclear.

In the present study, we evaluated the relative mRNA expression levels of Rab25 in HCC tissues and corresponding adjacent normal tissues. The outcome suggested that Rab25 gene expression was obviously increased in HCC tissue samples compared to that in normal tissues. It revealed that Rab25 might exhibit tissue-specific function as an oncogene in HCC. This result was accorded with the previous studies. A study of Mitra et al. demonstrated that the mRNA and protein expression levels of Rab25 were significantly elevated in breast cancer cell lines [19]. In the study of Sheach et al., tissue microarray section showed the protein expression of Rab25 was higher in ovarian cancer [20].

To explore the effect of Rab25 on the progression of HCC, we analyzed the relationship between Rab25 expression and clinical characteristics of patients. Interestingly, patients with high Rab25 expression tended to have advanced TNM stage, positive metastasis and high invasion classification which were aggressive clinical parameters representing advanced progression, invasion and metastasis. Similar findings were occurred in other cancers. Li et al. mentioned that the increased expression level of Rab25 was closely associated with invasion classification, lymph node metastasis and pathological stage of renal cell carcinoma patients [21]. In gastric cancer, elevated Rab25 expression was more often observed in patients with late pathological stage, positive lymph node metastasis and distant metastasis [22]. According to these studies, we hypothesized that Rab25 expression was involved in the development of human tumors, including HCC.

Recently, some clinical factors, such as serum AFP level, TNM stage and metastasis, are shown to be associated with the prognosis of HCC [23]. However, they may not accurately assess the prognosis due to heterogeneity in HCC patients. In this study, Rab25 expression was closely correlated with TNM stage and metastasis, suggesting Rab25 might be linked with the prognosis of HCC. Furthermore, the result of Kaplan-Meier analysis showed that patients with high expression of Rab25 had markedly shorter overall survival than those with low Rab25 expression. Univariate and multivariate cox regression analyses indicated that Rab25 might be an independent prognostic factor of HCC. Similar to our finding, a large number of researches had demonstrated that Rab25 had potency to predict the overall survival and disease-free survival of tumors [24, 25]. Moreover, metastasis and TNM stage both were independent factors in this study.

Conclusions

In conclusion, we prove that Rab25 expression is up-regulated in HCC and correlated with tumor progression. Besides, Rab25 may be an independent prognostic factor of HCC. However, considering the
constraints of samples size and its source, further studies are needed.

**List Of Abbreviations**

quantitative real-time polymerase chain reaction (qRT-PCR)
hepatocellular carcinoma (HCC)
standard deviation (SD)
rat sarcoma (Ras)

**Declarations**

**Ethics approval and consent to participate**

This study was supported by the Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College and also has been carried out in accordance with the World Medical Association Declaration of Helsinki.

**Consent for publication**

We obtaining permission from participants to publish their data.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

Not applicable.

**Authors’ contributions**

Z.D., H.Y. design of the work; X.H., Y.L. the acquisition, analysis, Y.L., S.L. interpretation of data; S.L., X.J. the creation of new software used in the work; X.H. have drafted the work or substantively revised it. All
authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Liu J, Ni W, Qu L, Cui X, Lin Z, Liu Q, Zhou H, Ni R. Decreased Expression of EHD2 Promotes Tumor Metastasis and Indicates Poor Prognosis in Hepatocellular Carcinoma. Digestive diseases sciences. 2016;61(9):2554–67.

2. Chen Y, Yang S, Hu J, Yu C, He M, Cai Z. Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma. PloS one. 2016;11(5):e0154939.

3. Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open access Macedonian journal of medical sciences. 2015;3(4):732–6.

4. Ha SY, Kim JH, Yang JW, Bae H, Cho HY, Park CK. Expression of DBC1 is associated with poor prognosis in hepatitis virus-related hepatocellular carcinoma. Pathol Res Pract. 2016;212(7):616–21.

5. Zhu Q, Qiao GL, Zeng XC, Li Y, Yan JJ, Duan R, Du ZY. Elevated expression of eukaryotic translation initiation factor 3H is associated with proliferation, invasion and tumorigenicity in human hepatocellular carcinoma. Oncotarget. 2016;7(31):49888–901.

6. Li J, Zhao X, Wang D, He W, Zhang S, Cao W, Huang Y, Wang L, Zhou S, Luo K. Up-regulated expression of phospholipase C, beta1 is associated with tumor cell proliferation and poor prognosis in hepatocellular carcinoma. OncoTargets therapy. 2016;9:1697–706.

7. Agarwal R, Jurisica I, Mills GB, Cheng KW. The emerging role of the RAB25 small GTPase in cancer. Traffic. 2009;10(11):1561–8.

8. Recchi C, Seabra MC. Novel functions for Rab GTPases in multiple aspects of tumour progression. Biochemical Society transactions. 2012;40(6):1398–403.

9. Mitra S, Cheng KW, Mills GB. Rab GTPases implicated in inherited and acquired disorders. Semin Cell Dev Biol. 2011;22(1):57–68.

10. Subramani D, Alahari SK. Integrin-mediated function of Rab GTPases in cancer progression. Mol Cancer. 2010;9:312.

11. Yin YX, Shen F, Pei H, Ding Y, Zhao H, Zhao M, Chen Q. Increased expression of Rab25 in breast cancer correlates with lymphatic metastasis. Tumour biology: the journal of the International Society for Oncodevelopmental Biology Medicine. 2012;33(5):1581–7.

12. Zhao M, Yin YX, Guo F, Yang YY, Shen F, Chen Q. Increased Rab25 expression is not correlated with peritoneal metastasis of ovarian cancers. Cancer investigation. 2012;30(9):683–7.
13. Liu Y, Tao X, Jia L, Cheng KW, Lu Y, Yu Y, Feng Y. Knockdown of RAB25 promotes autophagy and inhibits cell growth in ovarian cancer cells. Mol Med Rep. 2012;6(5):1006–12.
14. Geng D, Zhao W, Feng Y, Liu J. Overexpression of Rab25 promotes hepatocellular carcinoma cell proliferation and invasion. Tumour biology: the journal of the International Society for Oncodevelopmental Biology Medicine. 2016;37(6):7713–8.
15. Goldenring JR. A central role for vesicle trafficking in epithelial neoplasia: intracellular highways to carcinogenesis. Nature reviews Cancer. 2013;13(11):813–20.
16. Mitra S, Cheng KW, Mills GB. Rab25 in cancer: a brief update. Biochemical Society transactions. 2012;40(6):1404–8.
17. Caswell PT, Spence HJ, Parsons M, White DP, Clark K, Cheng KW, Mills GB, Humphries MJ, Messent AJ, Anderson KI, et al. Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Developmental cell. 2007;13(4):496–510.
18. Cheng KW, Agarwal R, Mitra S, Lee JS, Carey M, Gray JW, Mills GB. Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO molecular medicine. 2012;4(2):125–41.
19. Mitra S, Federico L, Zhao W, Dennison J, Sarkar TR, Zhang F, Takiar V, Cheng KW, Mani S, Lee JS, et al. Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. Oncotarget. 2016;7(26):40252–65.
20. Sheach LA, Adeney EM, Kucukmetin A, Wilkinson SJ, Fisher AD, Elattar A, Robson CN, Edmondson RJ. Androgen-related expression of G-proteins in ovarian cancer. British journal of cancer. 2009;101(3):498–503.
21. Li Y, Jia Q, Zhang Q, Wan Y. Rab25 upregulation correlates with the proliferation, migration, and invasion of renal cell carcinoma. Biochem Biophys Res Commun. 2015;458(4):745–50.
22. Cao C, Lu C, Xu J, Zhang J, Li M. Expression of Rab25 correlates with the invasion and metastasis of gastric cancer. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu. 2013;25(2):192–9.
23. Li M, Yan S, Cai M, Lu J, Zhang M, Yang P, Luo R. High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study. Molecular clinical oncology. 2016;4(2):159–65.
24. Ma YF, Yang B, Li J, Zhang T, Guo JT, Chen L, Li M, Chu J, Liang CY, Liu Y. Expression of Ras-related protein 25 predicts chemotherapy resistance and prognosis in advanced non-small cell lung cancer. Genetics molecular research: GMR. 2015;14(4):13998–4008.
25. Zhang J, Wei J, Lu J, Tong Z, Liao B, Yu B, Zheng F, Huang X, Chen Z, Fang Y, et al. Overexpression of Rab25 contributes to metastasis of bladder cancer through induction of epithelial-mesenchymal transition and activation of Akt/GSK-3beta/Snail signaling. Carcinogenesis. 2013;34(10):2401–8.

Figures
Figure 1

The relative mRNA expression levels of Rab25 in HCC tissues and paired adjacent normal tissues. Compared with normal tissues, the expression of Rab25 was obviously up-regulated in HCC tissue samples at mRNA level (P<0.001). *** indicated P less than 0.001.

Figure 2

Kaplan-Meier analysis for the overall survival of HCC patients. The overall survival of patients with low expression of Rab25 was significantly longer than those with high Rab25 expression (log rank test, P<0.001).